glp-1 dose conversion chart semaglutide to tirzepatide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks GLP-1 Phase-3 Impurity Challenges alhena_ingest Quantity:6 Months

glp-1 dose conversion chart semaglutide to tirzepatide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks GLP-1 Phase-3 Impurity Challenges alhena_ingest Quantity:6 Months

GLP-1 Phase-3 Impurity Challenges | Daicel Pharma Standards

*Data from published abstract, clinicaltrial.gov or from press-release by the manufacturing company **obesity trial, ^ Ratio of week 68 to baseline A data presented as efficacy estimand, B efficacy estimand data not available, primary analysis is presented

alhena_ingest

Quantity:6 Months

Two design quirks, however, could make it cost more than it appears